ONLINE SUPPLEMENTARY DATA

Supplementary Table 1: Visit schedule

	Visit 1 (V1)		**Visit 2 (V2)**	**Visit 3 (V3)**	**Visit 4 (V4)**
Timing of visits					
Situation 1†	Day 0 (baseline)		Day 1-3	Day 48-62	1-3 days after V3
Situation 2†	Day 0 (baseline)		Day 1-7	Day 40-68	1-7 days after V3
Questionnaires and assessments	Prior to joint assessment training	After joint assessment training			
Joint assessment training		x		x*	
Patient performed joint assessment	x	x	x	x	x
HCP performed joint assessment	x		x	x	x
Ultrasonography	x		x	x	x
HAQ	x		x	x	x
VAS pain, fatigue, and global health	x		x	x	x
CRP	x			x	

HCP; Healthcare professionals, HAQ; Health Assessment Questionnaire, VAS; Visual Analogue Scale, CRP; c-reactive protein

*only half the patients received repeated training at visit 3

† Intra-rater reliability of the per-protocol were assessed at two different time points; situation 1 and situation 2, and compared (table 2)

Supplementary Table 2: Patient characteristics grouped by country

	CZ Patients (n=79)	**DK patients (n=108)**	**P value**
Age, years	51.4 (12.9) †	57.8 (13.3)	<0.001
Female, n (%)	67 (85%)	84 (78%)	0.007
Disease duration, years	NA	11.9 (8.7)	NA
csDMARD use, n (%)	70 (90%)§	84 (83%)§	0.005
bDMARD use, n (%)	6 (8%)††	37 (37%)††	<0.001
Prednisolone use, n (%)	26 (33%)††	13 (13%)††	<0.001
DAS28CRP	2.9 (1.1) ‖	3.0 (1.0) ‖	0.675
VAS global (0-100), median [IQR]	21 [7.0;42.5]	23 [8.0;47.0]	0.710
VAS pain (0-100), median [IQR]	18 [6.0;38.0]	17 [7.0;38.0]	0.831
VAS fatigue (0-100), median [IQR]	18 [8.5;46.5]	31 [16.5;58.5]	0.003

Data is presented as mean with corresponding standard deviations unless other is stated.

csDMARD; conventional disease modifying antirheumatic drug, bDMARD; biologic disease modifying antirheumatic drug, DAS28CRP; disease activity score 28 c-reactive protein, VAS; visual analogue scale, IQR, interquartile range, CZ; Czech Republic, DK; Denmark

*Baseline data for DAS28CRP are those measured by HCP at visit 1.

†Data missing for 1 patient. §Data missing for 7 (DK) and 1 (CZ) patients. ††Data missing for 8 (DK) and 1 (CZ) patients. ‖ Data missing for 12 (DK) and 32 (CZ) patients.

Supplementary Table 3: Patients DAS28CRP intra-rater reliability grouped by country

	Intra-rater reliability (CZ)			**Intra-rater reliability (DK)**		
Variables	**Number of patients, n**	**ICC (95%CI)**	**MDC**	**Number of patients, n**	**ICC (95%CI)**	**MDC**
Visit 1†, all [primary]	79	0.88 (0.80 to 0.92)	1.14	108	0.87 (0.81 to 0.91)	1.13
Visit 3†, all	79	0.95 (0.93 to 0.97)	0.78	108	0.89 (0.85 to 0.92)	1.13
Visit 3†, subgroup A	41	0.95 (0.92 to 0.98)	0.80	61	0.92 (0.86 to 0.95)	0.99
Visit 3†, subgroup B	38	0.96 (0.92 to 0.98)	0.77	47	0.86 (0.76 to 0.92)	1.28
Visit 1 pre-training‡, all	79	0.91 (0.87 to 0.94)	0.97	108	0.89 (0.84 to 0.92)	1.00

Data presented includes the assessment of intra-rater reliability in the PP population with short time follow up performed within 1-7 days.

DAS28CRP; disease activity score 28 c-reactive protein, ICC; intraclass correlation coefficient, CI; confidence interval, MDC; minimal detectable change, CZ; Czech Republic, DK; intra-rater reliability

† For intra-rater reliability, visit 1 is compared with visit 2 and visit 3 is compared with visit 4.

‡ For intra-rater reliability, visit 1 pre-training is compared to visit 1 post-training.

Supplementary Figure 1: Observed agreement comparing joint assessments performed by patients, health care professionals and ultrasound



Pt; patient, HCP; health care professional, US; ultrasound

Inter-rater observed agreement for swollen and tender joints were assessed on single joint level and reported as absolute agreement.

Data shown as an average percentage of the agreement for all joints in all patients with error bars representing the range of observed agreement on single joint level.